(R)-2-methyl-N-methylsuccinimide | 15542-96-8

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-2-methyl-N-methylsuccinimide
• 英文别名: 1,3-dimethylpyrrolidine-2,5-dione；(R)-1,3-Dimethylpyrrolidine-2,5-dione；(3R)-1,3-dimethylpyrrolidine-2,5-dione
• CAS: 15542-96-8
• 化学式: C₆H₉NO₂
• 分子量: 127.143
• InChiKey: NIXKACOKLPRDMY-SCSAIBSYSA-N

物化性质

• 沸点：
  115-117 °C(Press: 17.5 Torr)
• 密度：
  1.127±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2925190090

反应信息

• 作为产物：
  描述：

  1,3-二甲基吡咯-2,5-二酮 在 enoate reductase YqjM from Bacillus subtilis 作用下， 以 乙醇 为溶剂， 生成 (R)-2-methyl-N-methylsuccinimide
  参考文献：
  名称：

  重组蓝细菌通过水的生物催化氧化促进C = C键的不对称还原

  摘要：

  重组的烯酸还原酶在蓝细菌中表达，用于光催化的C = C键的对映选择性还原。氧化还原酶与自然光合作用的耦合允许由水的氧化助长的不对称合成。绕过牺牲性共衬底的添加作为电子给体，大大提高了原子效率，并避免了不希望有的副产物的形成。产物形成的关键因素是NADPH的可用性和细胞中活性酶的量。该反应的效率可与大肠杆菌中典型的全细胞生物转化相媲美。在优化条件下，将100 mg前手性2-甲基马来酰亚胺溶液还原为光学纯的2-甲基琥珀酰亚胺（99％  ee，分离产物的产率为80％）。高产品收率和出色的光学纯度证明了使用重组蓝细菌进行光催化全细胞生物转化的合成有用性。

  DOI：

  10.1002/anie.201601200

文献信息

• CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION
  申请人：Fresenius Kabi Deutschland GmbH

  公开号：US20150297738A1

  公开（公告）日：2015-10-22

  The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS′(-L-M) n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS′ is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.

  本发明涉及一种羟烷基淀粉共轭物及其制备方法，所述羟烷基淀粉共轭物包括羟烷基淀粉衍生物和细胞毒性药剂，所述细胞毒性药剂包括至少一个次级羟基，其中羟烷基淀粉通过所述次级羟基与细胞毒性药剂连接。根据本发明的共轭物具有以下公式HAS'(-L-M)n的结构，其中M是细胞毒性药剂的残基，L是连接基团，HAS'是羟烷基淀粉衍生物的残基，n大于或等于1，且羟烷基淀粉衍生物的平均分子量（MW）高于肾脏阈值。
• AMIDINE CATALYST FOR CURABLE COMPOSITIONS
  申请人：SIKA TECHNOLOGY AG

  公开号：US20180179165A1

  公开（公告）日：2018-06-28

  The present invention relates to an amidine of the formula (I) and its use as a catalyst for crosslinking a curable composition. The amidine of the formula (I) contains at least one aliphatic amidine group. It is substantially odorless and nonvolatile at room temperature and accelerates the crosslinking of curable compositions very efficiently, without impairing the storage stability of the compositions. It is particularly suitable for compositions based on polymers containing silane groups, with which it is compatible, as a result of which such compositions do not have a tendency to separation or migration or evaporation of the catalyst.

  本发明涉及一种公式（I）的酰胺衍生物及其作为可固化组合物交联催化剂的用途。公式（I）的酰胺衍生物包含至少一个脂肪族酰胺基团。该酰胺衍生物在室温下几乎无味且不挥发，在不损害组合物的储存稳定性的情况下，能够高效地加速可固化组合物的交联反应。它特别适用于基于含有硅烷基的聚合物的组合物，因为它与这些聚合物兼容，从而使得这些组合物不具有催化剂分离、迁移或挥发的倾向。
• NOVEL MAYTANSINOID DERIVATIVES WITH PEPTIDE LINKER AND CONJUGATES THEREOF
  申请人：ImmunoGen, Inc.

  公开号：US20160263238A1

  公开（公告）日：2016-09-15

  The invention relates to novel cell-binding agent-cytotoxic agent conjugate having a peptide linkers and more specifically to conjugates of formula (I). The invention also provides novel cytotoxic agents of formula (II), linker compounds represented by formula (III), and drug-linker compounds represented by formula (IV). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.

  本发明涉及一种具有肽连接剂的新型细胞结合剂-细胞毒剂结合物，更具体地涉及公式(I)的结合物。本发明还提供了公式(II)的新型细胞毒剂、公式(III)所表示的连接剂化合物以及公式(IV)所表示的药物-连接剂化合物。本发明还提供了使用本发明的化合物或结合物抑制异常细胞生长或治疗哺乳动物的增殖性疾病的组合物和方法。
• Modified compound of andrographolide
  申请人：Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.

  公开号：US10717720B2

  公开（公告）日：2020-07-21

  The present disclosure discloses a modified compound of andrographolide, and particularly discloses a compound shown in formula (I) and (II) or a pharmaceutically acceptable salt thereof.

  本公开披露了穿心莲内酯的改良化合物，特别是披露了式 (I) 和 (II) 所示的化合物或其药学上可接受的盐。
• Asymmetric bioreduction of activated carbon–carbon double bonds using Shewanella yellow enzyme (SYE-4) as novel enoate reductase
  作者：Naseem Iqbal、Florian Rudroff、Ann Brigé、Jozef Van Beeumen、Marko D. Mihovilovic

  DOI：10.1016/j.tet.2012.05.092

  日期：2012.9

  Shewanella yellow enzyme (SYE-4), a novel recombinant enoate reductase, was screened against a variety of different substrates bearing an activated double bond, such as unsaturated cyclic ketones, diesters, and substituted imides. Dimethyl- and ethyl esters of 2-methylmaleic acid were selectively reduced to (R)-configured succinic acid derivatives and various N-substituted maleimides furnished the desired (R)-products in up to >99% enantiomeric excess. Naturally occurring (+)-carvone was selectively reduced to (-)-cis-dihydrocarvone and (-)-carvone was converted to the diastereomeric product, respectively. Overall SYE-4 proved to be a useful biocatalyst for the selective reduction of activated C=C double bonds and complements the pool of synthetic valuable enoate reductases. (C) 2012 Elsevier Ltd. All rights reserved.